SALT LAKE CITY, June 28, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics) announces the completion of its Memphis, TN research-feasibility activities and the establishment of its development phase operations and activities in Salt Lake City, UT.
Discgenics was founded in Memphis, TN during late 2007. The core to Discgenics' technology is a proprietary patented culture system that uses human nucleus pulposus (NP) tissue as a source for adult disc stem cells that can be expanded into therapeutic cell populations known as Discospheres™. These cells have different properties compared to traditional mesencyhmal stem cells and early research suggests that they may have a better capacity to regenerate NP tissue due to their direct origin within the disc and genetic footprint. Discgenics is developing an investigational product that provides the disc with new cells that can help restore the original properties of the disc.
Discgenics completed a successful "outside" third party scientific validation of its culture system and stem cell science during the first quarter of 2012. After receiving this validation, Discgenics transitioned its lab operations to the company's development phase location within the University of Utah's Cell Therapy and Regenerative Medicine Facility (CTRM) at Research Park in Salt Lake City. Discgenics' CEO, Flagg Flanagan said, "CTRM, which is part of the University of Utah Health Sciences, brings a synergistic opportunity to Discgenics. It provides access to both GLP lab and GMP stem cell production resources that can support both Discgenics product and stem cell process development needs."
About Discgenics, Inc.
Discgenics is a privately funded Spinal therapeutics company that is utilizing regenerative medicine and adult human disc stem cell technology to treat patients debilitated by degenerative disc disease. News and other information are available at: http://www.Discgenics.com.
Media Contact: Flagg Flanagan
Chief Executive Officer
SOURCE Discgenics, Inc.